Cargando…
Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C(0)) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C(0) and creatinine was performe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973796/ https://www.ncbi.nlm.nih.gov/pubmed/33737618 http://dx.doi.org/10.1038/s41598-021-85757-7 |
_version_ | 1783666897685839872 |
---|---|
author | Abumiya, Maiko Takahashi, Naoto Takahashi, Saori Yoshioka, Tomoko Kameoka, Yoshihiro Miura, Masatomo |
author_facet | Abumiya, Maiko Takahashi, Naoto Takahashi, Saori Yoshioka, Tomoko Kameoka, Yoshihiro Miura, Masatomo |
author_sort | Abumiya, Maiko |
collection | PubMed |
description | The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C(0)) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C(0) and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C(0) and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = − 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = − 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C(0) and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C(0) of 63.4–73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment. |
format | Online Article Text |
id | pubmed-7973796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79737962021-03-19 Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy Abumiya, Maiko Takahashi, Naoto Takahashi, Saori Yoshioka, Tomoko Kameoka, Yoshihiro Miura, Masatomo Sci Rep Article The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C(0)) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C(0) and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C(0) and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = − 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = − 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C(0) and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C(0) of 63.4–73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment. Nature Publishing Group UK 2021-03-18 /pmc/articles/PMC7973796/ /pubmed/33737618 http://dx.doi.org/10.1038/s41598-021-85757-7 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Abumiya, Maiko Takahashi, Naoto Takahashi, Saori Yoshioka, Tomoko Kameoka, Yoshihiro Miura, Masatomo Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title_full | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title_fullStr | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title_full_unstemmed | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title_short | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
title_sort | effects of slc22a2 808g>t polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973796/ https://www.ncbi.nlm.nih.gov/pubmed/33737618 http://dx.doi.org/10.1038/s41598-021-85757-7 |
work_keys_str_mv | AT abumiyamaiko effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT takahashinaoto effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT takahashisaori effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT yoshiokatomoko effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT kameokayoshihiro effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT miuramasatomo effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy |